Scarica l'app Stockscreener
32.58
1.19%
0.34
Cg Oncology Inc Borsa (CGON) Ultime notizie
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting - The Manila Times
CG Oncology to Present Phase 3 Trial Results for Bladder Cancer Treatment at SUO Meeting | CGON Stock News - StockTitan
CG Oncology, Inc. to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology 25th Annual Meeting - Marketscreener.com
CG Oncology, Inc. (NASDAQ:CGON) Sees Large Decline in Short Interest - MarketBeat
CG Oncology FY2024 EPS Estimate Lifted by Cantor Fitzgerald - MarketBeat
Los Angeles Capital Management LLC Takes $832,000 Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Lifesci Capital Boosts Earnings Estimates for CG Oncology - Defense World
FY2024 EPS Estimates for CG Oncology Raised by HC Wainwright - MarketBeat
CG Oncology FY2024 EPS Forecast Increased by Lifesci Capital - MarketBeat
CG Oncology, Inc. (CGON) Quarterly 10-Q Report - Quartzy
CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
CG Oncology (NASDAQ:CGON) Releases Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
HC Wainwright Reiterates "Buy" Rating for CG Oncology (NASDAQ:CGON) - MarketBeat
CG Oncology Posts $20.4M Loss, Maintains $540M Cash Reserve Through 2027 | CGON Stock News - StockTitan
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer - The Manila Times
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating - The Bakersfield Californian
CG Oncology, Inc. Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer - Marketscreener.com
TimesSquare Capital Management LLC Purchases 94,010 Shares of CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
CG Oncology's Breakthrough Bladder Cancer Drug Scores Second Nature Medicine Publication | CGON Stock News - StockTitan
CG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Receives $63.88 Consensus Target Price from Analysts - MarketBeat
CG Oncology, first biotech IPO for 2024, surges on trading debut - MSN
Vanguard Group Inc's Strategic Acquisition of CG Oncology Inc Sh - GuruFocus.com
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
CG Oncology To Report Final Results From CORE-001 Bladder Cancer Study Next Month - RTTNews
CG Oncology, Inc. (NASDAQ:CGON) Short Interest Down 14.5% in October - Defense World
UBS Initiates Coverage of CG Oncology (CGON) with Buy Recommendation - MSN
CG Oncology (NASDAQ:CGON) Coverage Initiated by Analysts at UBS Group - MarketBeat
Oncolytic Adenovirus Market Targets USD 250 Billion Valuation by 2033 at a 7.5% of CAGR - PharmiWeb.com
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Oncolytic Virus Market Size is Set for Rapid Growth as Innovative - openPR
17,595 Shares in CG Oncology, Inc. (NASDAQ:CGON) Acquired by SG Americas Securities LLC - MarketBeat
Down rounds don’t aid post-IPO performance - BioCentury
CG Oncology (NASDAQ:CGON) Earns "Buy" Rating from Bank of America - MarketBeat
The Potential Rise in the Price of Cg Oncology Inc. (CGON) following insiders activity - Knox Daily
Get in on Cg Oncology Inc.’s (CGON) buy-in window today! - SETE News
Renaissance Technologies LLC Grows Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Marshall Wace LLP Acquires New Shares in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth - Simply Wall St
Multiple players rev their Engenes in bladder cancer - BioWorld Online
Point72 Asset Management L.P. Sells 75,827 Shares of CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Want To Improve Study Startup? Get More Efficient - Clinical Leader
We Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business Growth - Yahoo Finance
How does Cg Oncology Inc. (CGON) change from a tortoise to a hare? - SETE News
RBC Capital Mkts initates Cg Oncology Inc. (CGON) stock to an Outperform - Knox Daily
CG Oncology, Inc. (NASDAQ:CGON) Shares Sold by Perceptive Advisors LLC - MarketBeat
Ensign Peak Advisors Inc Buys New Holdings in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Wall Street SWOT: CG Oncology stock poised for growth in bladder cancer market - Investing.com
Midday Stock Roundup: Indie Shares Down 5% - Orange County Business Journal
Wall Street SWOT: CG Oncology stock poised for growth in bladder cancer market By Investing.com - Investing.com South Africa
Goldman Sachs maintains $52 target on CG Oncology shares By Investing.com - Investing.com Canada
Deerfield Management Company L.P. Series C Increases Stake in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Deerfield Management Company L.P. Series C Boosts Stock Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
There is no way Cg Oncology Inc. (CGON) can keep these numbers up - SETE News
CGON: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Deeper Dive: Understanding Cg Oncology Inc. (CGON) Through its Various Ratios - The Dwinnex
Cg Oncology Inc. [CGON] Stock sold by Insider Song Hong Fang for $23.0 million - Knox Daily
RBC Capital Initiates Coverage of CG Oncology (CGON) with Outperform Recommendation - MSN
Yu Fan Makes New $49.83 Million Investment in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
CG Oncology (NASDAQ:CGON) Shares Gap Up to $39.00 - MarketBeat
CG Oncology (NASDAQ:CGON) Earns Outperform Rating from Analysts at Royal Bank of Canada - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by Rhumbline Advisers - Defense World
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):